{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:24:43Z","timestamp":1783297483451,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtct.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:38:13Z","timestamp":1723556293000},"page":"1090.e1-1090.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-5445","authenticated-orcid":false,"given":"Omar","family":"Albanyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Kalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-781X","authenticated-orcid":false,"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ochoa-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2024.08.007_bib0001","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.08.007_bib0002","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2024.08.007_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.08.007_bib0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cger.2015.08.010","article-title":"Myelodysplastic syndromes and acute myeloid leukemia in the elderly","volume":"32","author":"Klepin","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.08.007_bib0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood."},{"issue":"30","key":"10.1016\/j.jtct.2024.08.007_bib0006","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2024.08.007_bib0007","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2024.08.007_bib0008","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.jtct.2024.08.007_bib0009","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jtct.2024.08.007_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbmt.2011.07.013","article-title":"Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC","volume":"18","author":"Chevallier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.08.007_bib0011","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.jtct.2024.08.007_bib0012","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.7150\/jca.46081","article-title":"Reduced-intensity versus myeloablative conditioning regimens for younger adults with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"11","author":"Ma","year":"2020","journal-title":"J Cancer"},{"issue":"16","key":"10.1016\/j.jtct.2024.08.007_bib0013","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","article-title":"Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity","volume":"2","author":"Eapen","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2024.08.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2024.08.007_bib0015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.08.007_bib0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.08.007_bib0017","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/bloodadvances.2021004192","article-title":"Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant","volume":"5","author":"Al Malki","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2024.08.007_bib0018","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2024.08.007_bib0019","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood."},{"issue":"282","key":"10.1016\/j.jtct.2024.08.007_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2024.08.007_bib0021","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"10.1016\/j.jtct.2024.08.007_bib0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.jtct.2024.08.007_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc: Ser. B (Method)"},{"issue":"4","key":"10.1016\/j.jtct.2024.08.007_bib0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.jtct.2024.08.007_bib0025","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbmt.2017.09.003","article-title":"Comparison of conditioning with fludarabine\/busulfan and fludarabine\/melphalan in allogeneic transplantation recipients 50 years or older","volume":"23","author":"Kawamura","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.08.007_bib0026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2024.08.007_bib0027","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/10428194.2020.1731498","article-title":"Reduced-intensity fludarabine\/melphalan confers similar survival to busulfan\/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia","volume":"61","author":"DiMaggio","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2024.08.007_bib0028","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bbmt.2016.04.026","article-title":"Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing","volume":"22","author":"Damlaj","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.08.007_bib0029","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbmt.2013.07.008","article-title":"A randomized phase II trial of fludarabine\/melphalan 100 versus fludarabine\/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma","volume":"19","author":"Bashir","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.08.007_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbmt.2004.10.007","article-title":"Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease","volume":"11","author":"Goldberg","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.08.007_bib0031","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V86.3.890.890","volume":"86","author":"Holler","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.08.007_bib0032","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.08.007_bib0033","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3324\/haematol.2013.088781","article-title":"Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial","volume":"99","author":"Jim","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2024.08.007_bib0034","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bmt.2009.66","article-title":"Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU\/MEL conditioning regimen in context with BU\/CY2","volume":"44","author":"Vokurka","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.08.007_bib0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","article-title":"Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.08.007_bib0036","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","article-title":"A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation","volume":"34","author":"Bolwell","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.08.007_bib0037","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma","volume":"25","author":"Saini","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:52:41Z","timestamp":1762048361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724005888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666636724005888"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.08.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}